#ESMO25: Novartis seeks to move Pluvicto to earlier prostate cancer, but data underwhelm

BERLIN — Novartis’ Pluvicto cut the risk of prostate cancer progression or death by 28% when added to hormone therapy, and the radiopharmaceutical also slowed progression to end-stage disease, according to the latest Phase 3 trial ...